



PRIMAGE
 Medical imaging
 Artificial intelligence
 Childhood cancer research

D9.3 – Record of Dissemination and Communication Activities in Year 1 and Plan for Year 2

Project Full Title: *PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers*

Project acronym: PRIMAGE

Project type: Horizon 2020 | RIA (Topic SC1-DTH-07-2018)

Grant agreement no: 826494

Document information:

Deliverable no.	D9.3
Title	Record of Dissemination and Communication Activities in Year 1 and Plan for Year 2
Work Package	WP9
Dissemination level	Report/Public
Nature	
Responsible partner	SIOP Europe
Main Contact person	Samira Essiaf
Deliverable due submission date	30/11/2019
Deliverable actual submission date	

Document validation:

Validated by	Name	Organisation short name	Visa
Responsible	Samira Essiaf, Anne Blondeel	SIOPE	OK
Reviewer 1	Laura Muñoz	MATICAL	OK
Reviewer 2	Gracia Marti	HULAFE	OK

History of changes:

Change explanation	Pages affected	Change made by (Name & surname)	Date
Incorporated reviewers comments and suggestions	All	Anne Blondeel	26/11/2019



Table of Contents

1. INTRODUCTION	3
2. DISSEMINATION ACTIONS	3
2.1 OBJECTIVES AND PROCEDURES.....	3
2.2 KEY ACTIONS AND TARGET AUDIENCE.....	3
2.3 DISSEMINATION TOOLS.....	4
3. EVALUATION	19
4. PLAN FOR YEAR 2	20
5. PROJECT DOCUMENTS.....	22

Disclaimer

The opinions stated in this report reflects the opinions of the authors and not the opinion of the European Commission.

All intellectual property rights are owned by the consortium of PRIMAGE under terms stated in their Consortium Agreement and are protected by the applicable laws. Reproduction is not authorized without prior written agreement. The commercial use of any information contained in this document may require a license from the owner of the information.

Acknowledgement

This document is a deliverable of the PRIMAGE project. This project has received funding from the European Union´s Horizon2020 research and innovation programme under grant agreement no.: 826494.



1. Introduction

This report, entitled “Record of Dissemination and Communication Activities in Year 1 and Plan for Year 2” will outline how the objectives set out in D9.2, “First Year Plan for Dissemination and Communication of Project Results” were carried out and achieved. Furthermore, this report will outline the strategy for ensuring the continued and efficient dissemination of PRIMAGE activities, progress and achievements during the second year of the project.

The different sections of this report will address the actions that were taken by SIOPE and its partners during M1-M12 of the PRIMAGE Project, showing how optimal visibility and wide outreach to all stakeholders was achieved using the toolkit which was developed, as well as how results were disseminated to the scientific community, using the appropriate communication channels and dissemination tools.

The D9.2 plan, together with the dissemination toolkit, were submitted to the EC Funding and Tender Portal on the 31st of March, 2019. It is also available from the PRIMAGE shared document repository here: <https://drive.google.com/drive/u/0/folders/1Z8bc18BDzaMmk8cKvQpzBQLiBukJ8ky4>.

Links to the elements in the toolkit are included at the end of this document.

2. Dissemination Actions

2.1 Objectives and Procedures

The purpose of the dissemination actions are to disseminate and communicate about the activities of PRIMAGE and to ensure that the desired impact of PRIMAGE is achieved.

Specifically, the objectives are to:

- Raise awareness – let others know what we are doing
- Inform – educate the community
- Engage – get input and feedback from the community
- Promote – disseminate our outputs and results

In order to ensure a highly efficient dissemination of scientific information at the European level, the PRIMAGE consortium created and carried out key communication actions addressed in WP9 in order to implement the best way to promote the project's results. To raise scientific and public awareness on PRIMAGE'S progress, systematic public information was and will continue to be disseminated through internal and external dissemination routes as detailed in the sections below.

2.2 Key actions and Target Audience

SIOPE Europe, together with the consortium partners carried out the following tasks:

- Implemented the strategy for internal and external dissemination;
- Publicised the project to all relevant network stakeholders;
- Identified the most appropriate results to be announced to relevant target audiences by means of publications and information outlets/tools;
- Identified and maintained a database or PRIMAGE Roadshow of events of the most efficient opportunities to reach these target audiences;
- Fostered networking within the scientific community, specifically with other EU funded initiatives and associations.



SIOP Europe, together with the WP9 partners organised actions to increase the visibility of PRIMAGE for respective consortium partners (internal) and other communities (external).

The internal target groups are:

- The PRIMAGE Consortium Partners: 16 project partners, including 3 clinical partners and 13 technical partners;
- The PRIMAGE Advisory Board which consists of a recognized group of experts in the fields of Pediatric oncology, Imaging biomarkers and related ICT technologies, GDPR (Data Protection and Treatment aspects) and industry representatives (Pharma and PACS industry). The Advisory Board oversees the PRIMAGE project work progress and its main goal is to give general advice and guidance to the Consortium.
- The partner's respective communities and stakeholders.

The external target groups are:

- Scientific Community, healthcare and research professionals in the
 - Oncology community
 - Paediatric haemato-oncology community
 - ICT-related community
- Associations in paediatric oncology and in-silico technologies (e.g., CCI Europe, ECCO, ESTRO, EIBIR, ESR, AVICENNA Alliance, European Society of Medical Imaging Informatics (EuSoMII))
- Networks and platforms of other EU-funded initiatives (e.g., ERN PaedCan, Joint Action on Rare Cancers, VirtualBrainCloud, Big Data for Better Outcomes, Innovative Medicines Initiative, Electronic Health Records for Clinical Research, EUPID, Eureka)
- Policy makers: EU institutions and (sub)national authorities
- Industry: pharmaceutical and medical device organisations
- End users: patient associations, national healthcare systems
- General public

2.3 Dissemination Tools

To achieve the project dissemination and communication objectives, and to reach the different target audiences and channels, the following project tools were developed:

Project Identity

- Project logo
- Templates for graphical layout of project documents
- Correct use of the EU emblem,
- Dissemination toolkit (brochure, presentation, poster, pop-up banner):
https://drive.google.com/file/d/1gzAWKRjQYKEUIWt7CiLG-pD-sIIM_MyT/view?usp=sharing



Predictive In-silico Multiscale Analytics to support cancer personalized diagnosis and prognosis, Empowered by imaging biomarkers



Project Purpose

This project proposes an open cloud-based platform to support decision making in the clinical management of two paediatric cancers, **Neuroblastoma (NB)**, the most frequent solid cancer of early childhood, and the **Diffuse Intrinsic Pontine Glioma (DIPG)** the leading cause of brain tumour-related death in children.

PRIMAGE platform implements the latest advancement of in-silico imaging biomarkers and modelling of tumour growth towards a personalized diagnosis, prognosis and therapies follow-up.


Project Details

Budget: 10,3M €
Duration: 4 years


Coordinator: Dr. Martí Borrero, Head of Medical Imaging Department, at Hospital Universitario y Politécnico La Fe in Valencia (Spain). Dr. Cañete, Head of the Paediatric Oncology Unit at HULAFE, is leading the clinical part of PRIMAGE's project.

Consortium: Partners from 16 European institutions, including Hospitals, R&D Centres, Medical Associations, Private Companies and Universities from 8 European countries (Spain, Germany, France, Austria, United Kingdom, Belgium, Poland and Italy).

Enabling technologies integrating PRIMAGE Platform



PRIMAGE Application in the Clinical Setting



www.primageproject.eu

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 826494



PRIMAGE
Medical imaging
Artificial intelligence
Childhood cancer research

Predictive In-silico Multiscale Analytics to support cancer personalized diagnosis and prognosis, Empowered by Imaging biomarkers



www.primageproject.eu

[@primage_project](#) [/primageproject](#)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 826494

eNewsletter

A periodic eNewsletter or eBlast will be sent to consortium partners and their networks. It will be made available on the project website and via social media. The eNewsletter is meant to provide information on the project's progress, results and upcoming events. The frequency of the eNewsletter is yet to be determined based on progress and results, but it is expected to be issued twice per year, starting in year 2 of the project.

The first edition of the eNewsletter is expected to be sent to the consortium partner's members in December 2019.





PRIMAGE
Medical imaging
Artificial intelligence
Childhood cancer research

Newsletter | Winter 2020

About the PRIMAGE Project

The expected outcome of the project is to integrate and validate functional prototype of PRIMAGE cloud-based platform offering predictive tools to assist management of Neuroblastoma and DIPG paediatric cancers, from diagnosis to prognosis, therapies choice and treatment follow up, based on the use of novel imaging biomarkers, tumour growth models and advanced visualisation of predictions.

Neuroblastoma is the most common extracranial tumour in children. Every year in Europe, about 35,000 new cases of children and adolescents are diagnosed and 1 in every 300 newborns will develop cancer before reaching 20 years. Additionally, DIPG is a very rare tumour in children having a disastrous survival (10%) despite treatment and research. Unfortunately, there is no curative treatment for DIPG and radiotherapy (standard treatment) is only palliative.

SIOP Europe, two Imaging Biobanks and three of the most prominent European Paediatric oncology units are partners in this project, making retrospective clinical data (imaging, clinical, molecular and genetics) registries accessible to PRIMAGE, for training of machine learning algorithms and testing of the in-silico tools' performance.

Solutions to streamline and secure the data pseudonymisation, extraction, structuring, quality control and storage processes, will be implemented and validated also for use on prospective data, contributing to European shared data infrastructures.

UPCOMING EVENTS

date	date	date
location	location	location
info	info	info
read more >>	read more >>	read more >>

What is PRIMAGE?

PRIMAGE – Predictive In-silico Multiscale Analytics to support cancer personalised diagnosis and prognosis, Empowered by imaging biomarkers.

PRIMAGE is one of the largest and more ambitious European research projects in medical imaging, artificial intelligence and childhood cancer. The project is devoted at developing methods of **computational analysis of medical images applied to childhood cancer**.

PRIMAGE proposes an open **cloud-based platform to support decision making in the clinical management of malignant solid tumours**, offering predictive tools to assist diagnosis, prognosis, therapies choice and treatment follow up, based on the use of novel imaging biomarkers, in-silico tumour growth simulation, advanced visualisation of predictions with weighted confidence scores and machine-learning based translation of this knowledge into predictors for the most relevant, disease-specific, Clinical End Points.

The proposed data infrastructures, imaging biomarkers and models for in-silico medicine research will be validated in the application context of two paediatric cancers, **Neuroblastoma** (the most frequent solid cancer of early childhood) and the **Diffuse Intrinsic Pontine Glioma – DIPG** (the leading cause of brain tumour-related death in children).

ACCESS MORE INFO

E-mail: office@primageproject.eu

Visit our website: www.primagenproject.eu | Twitter: [#PRIMAGEproject](https://twitter.com/PRIMAGEproject)

PRIMAGE Roadshow of Events

Some of the most effective possibilities for disseminating knowledge are based on the participants' own initiatives, for example, in the course of attending meetings, conferences, workshops, training sessions, and seminars.

A PRIMAGE "Roadshow" of approximately 20 events was organised. This consisted of an agenda of relevant European and international events that occur during the duration of the project and that consortium members are already planning to attend or organise as part of their existing activities.

During Year 1, the PRIMAGE project was presented at the following events:



Dissemination at External Events	Event Details
ACCELERATE Congress	<p>14-15 February 2019, Brussels, Belgium https://www.siope.eu/2019/04/23/7th-accelerate-paediatric-oncology-conference/</p> <p>This year's edition focused on a number of important topics such as:</p> <ul style="list-style-type: none"> • Information sharing on the most recent successes in paediatric oncology drug development; • Discussion on new regulatory environments in the US (RACE for Children Act) and in Europe and on how to implement new oncology drug development for children in this new global landscape; • Addressing advancements in the ACCELERATE program including Paediatric Strategy Forums, Fostering Age Inclusive Research (FAIR) Trials, new models for paediatric drug development and international consensus on pre-clinical testing; • Fostering and strengthening international collaborations across countries and among the main target groups. <p>Attendance: Approximately 170 delegates from 30 countries, including experts from academia, industry, patient/parent/survivor advocacy groups, foundations and regulatory authorities.</p> <p>Dissemination: Primage brochure made available to participants.</p>
European Congress of Radiology (ECR)	<p>27 February – 3 March 2019, Vienna, Austria https://www.myesr.org/past-congresses/ecr-2019</p> <p>The ECR is the annual meeting of the ESR. It is a trend-setting, dynamic and service-oriented congress, well-known as one of the most innovative meetings within the scientific community, embedded in a unique and inspiring ambience. The ECR is an international meeting and one of the leading events in radiology. The ECR is one of the largest medical meetings in Europe and the second-largest radiological meeting in the world. The ECR attendees span all areas of the radiology arena including: radiology professionals, radiographers, physicists, industry representatives, and press reporters for both the medical and consumer press.</p> <p>Attendance: 30.000</p> <p>Dissemination: Several partners of the Primage consortium actively participated in this event. The Primage brochure was made available to participants.</p>
International Childhood Cancer Day	<p>6 March 2019, Brussels, Belgium https://www.siope.eu/activities/siopes-upcoming-events/conferences-and-events/past-events/international-childhood-cancer-awareness-day-european-parliament-brussels/</p> <p>This edition of the annual International Childhood Cancer Day (ICCD 2019) meeting officially unveiled the European Elections 2019 Manifesto for the paediatric oncology and haematology community: "Beating childhood cancer: Cure more and cure better – Towards zero deaths & zero late effects."</p> <p>Attendance: Approximately 150 policymakers, parents, patients, paediatric oncologists.</p> <p>Dissemination: Primage brochure made available to participants.</p>
American Association for Cancer Research Congress (AACR)	<p>29 March – 3 April 2019, Atlanta, GA, USA https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=174</p> <p>The AACR Annual Meeting 2019 brought together more than 21,000 laboratory researchers, clinicians, patient advocates, and other oncology professionals. As the leading forum for cutting-edge basic, translational, and clinical discoveries, the AACR Annual Meeting sets the research agenda for the international cancer community.</p>



D9.3_ Record of Dissemination and Communication Activities

	<p>Attendance: 21.000</p> <p>Dissemination: Primage brochure made available to participants.</p>
European Society for Radiotherapy & Oncology (ESTRO38)	<p>26-30 April 2019, Milan, Italy</p> <p>https://www.estro.org/congresses-meetings/items/estro-38</p> <p>'Targeting optimal care, together' was the theme of ESTRO 38, with a spotlight on the multiprofessional and multidisciplinary aspect of the specialty. The theme also represented the strength of all working towards a common goal for improved patient outcomes.</p> <p>Attendance: 6000</p> <p>Dissemination: Primage brochure made available to participants.</p>
5th EORTC Quality of Life Conference	<p>16-17 May 2019, Brussels, Belgium</p> <p>https://www.eortc.org/event/5th-eortc-quality-of-life/</p> <p>This event gave participants the opportunity to learn about the latest topics in quality of life (QOL) and patient reported outcomes research. The two-day conference brought together over 30 of the world's most influential QOL researchers. There were presentations on current state-of-the-art methods for instrument development and QOL measurement in international cancer clinical trials, addressing a variety of topics from designing robust measures to understanding their clinical meaning. Discussions on new tools and emerging technologies that have the potential to change the way we measure QOL, as well as on the rapidly growing field of electronic questionnaire administration.</p> <p>Attendance: 250</p> <p>Dissemination: Primage brochure made available to participants.</p>
SIOP Europe Annual Meeting	<p>20-24 May 2019, Prague, Czech Republic</p> <p>http://siopeurope.blueline015.cz/</p> <p>Hosted by the European Society for Paediatric Oncology (SIOP Europe), in partnership with CCI Europe, this Annual Meeting brought together the diverse stakeholders who are invested in tackling key issues with the aim of increasing the cure rate for cancers affecting children and adolescents and improving the quality of life for survivors.</p> <p>This event included the SIOP Europe Clinical Research Council (CRC) Meeting as well as the CCI Europe Annual Congress</p> <p>Attendance: 1400</p> <p>Dissemination: Primage brochure made available to participants.</p>
ASCO Annual Conference	<p>31 May - 4 June 2019, Chicago, IL, USA</p> <p>https://meetinglibrary.asco.org/browse-meetings/2019%20ASCO%20Annual%20Meeting</p> <p>The 2019 ASCO Annual Meeting, brought together more than 32,000 oncology professionals from across the globe. The theme of this year's conference was Caring for Every Patient, Learning From Every Patient.</p> <p>Attendance: 32.000</p> <p>Dissemination: Primage brochure made available to participants.</p>
Childhood Cancer Awareness Month	<p>September 2019</p> <p>During this month, SIOP Europe organised a social media campaign across all of its platforms, reaching a wide audience. This campaign included several tweets and posts disseminating the PRIMAGE Project to the community and general public.</p>
ECCO Summit	<p>12-14 September 2019, Brussels, Belgium</p> <p>https://www.eccosummit.eu/</p>



D9.3_ Record of Dissemination and Communication Activities

	<p>The ECCO 2019 European Cancer Summit brought together worldwide leaders from cancer care, research, patient advocacy and public-private sectors in a unique multi-stakeholder forum. The theme of the second edition of the ECCO Summit was: “European Cancer Care: Across Borders”.</p> <p>Attendance: 350</p> <p>Dissemination: Primage brochure made available to participants.</p>
EUSOMII	<p>18-19 October 2019, Valencia, Spain</p> <p>https://www.eusomii.org/events/eusomii-annual-meeting-valencia-25-26-october-2019/</p> <p>“Medical Imaging Informatics – AI, Clinical Applications and more”. During both days a combination of educational and scientific sessions were offered. In the first half of both days lectures were provided in the field of imaging informatics, and at the end of the second morning the attendees’ skills were tested with an examination, which contributes to the obtainment of a certificate in imaging informatics.</p> <p>Attendance: 150</p> <p>Dissemination: A presentation and a poster on PRIMAGE were presented by HULAFE.</p>
SIOP International Congress	<p>23-26 October, Lyon, France</p> <p>https://siop-congress.org/</p> <p>The caregivers, such as nurses, surgeons, paediatric and radiation oncologists involved in the care of children and teenagers with cancer and their parents from all around the world meet every year to share results, experience, difficulties, progress and new tools.</p> <p>Attendance: 1850</p> <p>Dissemination: Primage brochure made available to participants.</p>
JAIMA	<p>8 November 2019, Valencia, Spain</p> <p>https://www.acim.lafe.san.gva.es/acim/?p=7282&lang=es</p> <p>Attendance: 500</p> <p>Dissemination: Two presentations on PRIMAGE were presented by HULAFE: One on “Imaging Biomarkers in Pediatric Oncology” and another on “Paediatric Oncology in 2020”.</p>
Chinese Congress of Radiology	<p>13-17 November 2019, Beijing, China</p> <p>https://ccr2019.medmeeting.org/en</p> <p>Attendance: Unknown</p> <p>Dissemination: A presentation was made by HULAFE on the PRIMAGE Project.</p>



	
Dissemination at Internal Events	Event details
PRIMAGE Consortium Meeting	<p>26 June 2019 (M6), Pisa, Italy</p> <p>30 October 2019 (M12), Valencia, Spain</p> <p>All PRIMAGE Consortium Partners attended the M6 and M12 Consortium Meetings and presented the work done within their work packages.</p>

Furthermore, the list of events was kept up to date throughout the project via a spreadsheet tracking the partners' attendance at meetings. The spreadsheet can be accessed here:

https://docs.google.com/spreadsheets/d/1uNWS65ZClqWH-6AGyny7fkNzF-SKqk5UMba_jYKuk_0/edit?usp=sharing

Partner organisation	Author/presenter	Others involved	Activity type (PLEASE select from the list)	Title	Event / source name	Target audience (PLEASE select from the list)	Size of audience	Date/period	Venue/Place	Link/source
U. Pisa	E. Neri		Participation to a Conference	Imaging and Dose Biobanks	European Congress of Radiology	Scientific Community (Higher Education, Research)		28/02/2019	Vienna, Austria	
HULAFE-Gibi	Dr Luis Marti-Bonmati		Participation to a Conference		Annual Spanish Meeting on NB	Scientific Community (Higher Education, Research)		12/03/2019	ISLAFE, Valencia, Spain	
HULAFE-FOU	Dr Adela Cafete		Organisation of a Conference		Annual Spanish Meeting on NB	Scientific Community (Higher Education, Research)		12/03/2019	ISLAFE, Valencia, Spain	
HULAFE-Gibi	Dr Luis Marti-Bonmati		Participation to a Conference		European Congress of Radiology	Scientific Community (Higher Education, Research)		27/02/2019-3/3/2019	Vienna, Austria	
HULAFE-Gibi	Dr Luis Marti-Bonmati		Participation to a Conference		Avances en radiología diagnóstica y terapéutica y medicina física	Scientific Community (Higher Education, Research)			Universidad de Granada, Spain	
HULAFE-Gibi	Dr Luis Marti-Bonmati		Participation to a Conference	Ensayos clínicos con datos retrospectivos y biomarcadores de imagen	Sessions and Acts of the Royal National Academy of Medicine	Scientific Community (Higher Education, Research)		12/03/2019	Royal National Academy of Medicine	
Cyfronet	Dr Marian Bubak		Participation to a Workshop	In quest for reproducibility of medical simulations on e-infrastructures	Container Technologies in Cloud and High Performance Computing Research and Commercial Applications	Scientific Community (Higher Education, Research)	~35	29/03/2019	SURF Sara, Amsterdam Science Park (NL)	https://www.combiomed.eu/events/26combiomed-containerisation-meeting/
Medeprim	Karine Seymour		Participation to a Conference		Workshop eSanté CGSD - "Données, Big Data & Intelligence Artificielle en Oncologie"	Scientific Community (Higher Education, Research)		27/05/2019	Toulouse, France	
HULAFE-Gibi	Dr Poljzeni Gkontra		Participation to a Conference	Predictive in-silico multiscale analytics to support cancer personalized diagnosis and prognosis, empowered by imaging biomarkers	COMBINE 2019	Scientific Community (Higher Education, Research)		16/07/2019	Heidelberg, Germany	http://combine.org/events/COMBINE-2019/#registration
UKON	Hanna Schäfer		Organisation of a Workshop		Fourth International Workshop on Health Recommender Systems: (HealthRecSgs 2019)	Scientific Community (Higher Education, Research)	50	20/09/2019	Copenhagen, Denmark	
UPV-IZM	Ignacio Blanquer		Participation to a Workshop	Computational Back-ends for Artificial Intelligence in Childhood Cancer Research	Workshop on Cloud Networks - Conference of the Brazilian Computation Society	Scientific Community (Higher Education, Research)	100	16/09/2019	Belém, Brazil	https://thealthrecs.gs/hub.io/ https://www.associaçãobrasileira.edu.br/edu/bcco-2019-5th-july-agenda/#overlapping-content/cloud-edge-brasil-and-workshop-cloud-networks-2019
HULAFE-GIBI	Gracia Martí	Giuliana Resanta, Jan Meizner	Participation to a Workshop		Building EOSC through the H2020 projects - current status and future directions	Scientific Community (Higher Education, Research)	100	9/09/19 - 10-09/19	Brussels, Belgium	https://europeproject.eu/events/building-eosc-through-the-h2020-projects-current-status-and-future-directions
HULAFE	Leonor Cerdá		Participation to a Conference		EUSOM11					
HULAFE	Blanca Martínez		Participation to a Conference		JAMA					
HULAFE	Leonor Cerdá		Participation to a Conference		JAMA					
HULAFE	Luis Marti-Bonmati		Participation to a Conference		Chinese Congress of Radiology					
ANSYS	Yanfeng YE	Romain Flichepoll	Participation to a Workshop	Implementation of diffusion-growth coupled model in ANSYS Workbench	ANSYS Workshop	Scientific Community (Higher Education, Research)	15	16-17/09/2019	Zaragoza, Spain	

Publications

SIOP Europe, together with the consortium partners will encourage and monitor the timely publication of results in peer-reviewed journals and at international conferences, while ensuring that no conflicts with intellectual property rights arise.



A PRIMAGE Position Paper has been written by the consortium partners and submitted to the European Radiology Experimental journal. We are currently awaiting the comments from the reviewers.

Website

A PRIMAGE website was created. SIOP Europe, with input from the consortium partners is responsible for administering the website. It serves as the main contact point for external users and as the main dissemination platform for stakeholders. The website can be accessed here: www.primageproject.eu

PRIMAGE
Medical Imaging
Artificial Intelligence
Childhood cancer research

English

Search

Home Primage Project Partners Resources Events and News Contact Us

News

"Aiming at lethal paediatric tumours" – PRIMAGE Project in the European Hospital journal.

PRIMAGE at the European Open Science Cloud (EOSC) Concertation meeting

Concrete plans for the next steps of the PRIMAGE Project were made at Month-6 meeting

More news...

PRedictive In-silico Multiscale Analytics to support cancer personalized diagnosis and prognosis, Empowered by imaging biomarkers

PRIMAGE is one of the largest and more ambitious European research projects in medical imaging, artificial intelligence and childhood cancer.

About the project

The project, financed by the European Commission, has 16 European partners that are participating in the consortium and has an implementation duration of 4 years. Internationally recognized researches in in-silico technologies and clinical experts in pediatric cancer are part of the staff of PRIMAGE

This project proposes an open cloud-based platform to support decision making in the clinical management of two paediatric cancers, Neuroblastoma (NB), the most frequent solid cancer of early childhood, and the Diffuse Intrinsic Pontine Glioma (DIPG) the leading cause of brain tumour-related death in children.

PRIMAGE platform implements the latest advancement of in-silico imaging biomarkers and modelling of tumour growth towards a personalised diagnosis, prognosis and therapies follow-up.

Join our mailing list

Join our mailing list to receive all project updates.

Email address:
Your email address

By signing up I accept the SIOP Europe Privacy Policy

Sign up

PRIMAGE
Medical Imaging
Artificial Intelligence
Childhood cancer research

Project Coordinator
Dr. Marti-Bonmati, Head of Medical Imaging Department and Dr. Cañete, Head of the Paediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Project Management Team
Mario Aznar, MATICAL Innovation, Madrid, Spain
Gracia Marti, Project Manager, GIBI230, Hospital

Follow us
on Twitter
on Facebook

Sitemap



The PRIMAGE website user statistics can be found in the three charts below:

Total number of page views:

Page	Page Views	Page Value
/	1,371	\$0.00
/partners/	476	\$0.00
/project/	345	\$0.00
/partners/team-members/	236	\$0.00
/news-resources/	216	\$0.00
/events/	172	\$0.00
/project/project-approach-workplan/	130	\$0.00
/news-resources/publications/	101	\$0.00
/news-resources/communication-toolkit/	95	\$0.00
/partners/advisory-board/	90	\$0.00

Last 12 months ▼ [PAGES REPORT >](#)

Page views according to country:



D9.3_ Record of Dissemination and Communication Activities

Country ?	Acquisition		
	Users ? ↓	New Users ?	Sessions ?
	818 % of Total: 100.00% (818)	818 % of Total: 100.00% (818)	1,25 % of Total: 100.00% (1,25)
1.  Spain	228 (27.47%)	225 (27.51%)	395 (31.4%)
2.  Italy	97 (11.69%)	92 (11.25%)	136 (10.8%)
3.  United States	65 (7.83%)	65 (7.95%)	67 (5.3%)
4.  Germany	61 (7.35%)	60 (7.33%)	86 (6.8%)
5.  France	61 (7.35%)	61 (7.46%)	101 (8.0%)
6.  United Kingdom	60 (7.23%)	59 (7.21%)	91 (7.2%)
7.  Belgium	36 (4.34%)	35 (4.28%)	102 (8.1%)
8.  Austria	31 (3.73%)	30 (3.67%)	42 (3.3%)
9.  Poland	30 (3.61%)	30 (3.67%)	48 (3.8%)
10.  India	23 (2.77%)	23 (2.81%)	27 (2.1%)

Top referring sites:



D9.3_ Record of Dissemination and Communication Activities

Source ?	Acquisition		
	Users ? ↓	New Users ?	Sessions ?
	64 % of Total: 7.82% (818)	53 % of Total: 6.48% (818)	11 % of Total: 8.99% (1,25)
1. vis.uni-konstanz.de	9 (14.06%)	7 (13.21%)	12 (10.62)
2. cyfronet.krakow.pl	8 (12.50%)	7 (13.21%)	22 (19.47)
3. medexprim.com	8 (12.50%)	7 (13.21%)	9 (7.96)
4. mail.google.com	6 (9.38%)	3 (5.66%)	12 (10.62)
5. primageproject.us8.list-manage.com	6 (9.38%)	3 (5.66%)	24 (21.24)
6. quibim.com	5 (7.81%)	4 (7.55%)	5 (4.42)
7. ehealthnews.eu	3 (4.69%)	3 (5.66%)	4 (3.54)
8. baidu.com	2 (3.12%)	2 (3.77%)	2 (1.77)
9. comses.net	2 (3.12%)	2 (3.77%)	2 (1.77)
10. jobs.digital113.fr	2 (3.12%)	2 (3.77%)	2 (1.77)

Social Media

SIOPE Europe, together with some of the PRIMAGE project partners have been actively promoting the PRIMAGE project presence via social media on Twitter, LinkedIn, and Facebook. All social media posts include the hashtag **#PRIMAGEproject**.

Updates on the project status, news about upcoming meetings and events, updates on publications and other noteworthy items are widely shared via the social media platforms.

Consortium partners and stakeholders have been encouraged to use the dedicated hashtag **#PRIMAGEproject** to disseminate via their own social media channels.

The accounts/handles are as follows:

Twitter: @ PRIMAGEproject and @SIOPEurope

LinkedIn: <https://www.linkedin.com/company/primageproject>

Facebook: <https://www.facebook.com/SIOP-Europe-the-European-Society-for-Paediatic-Oncology-SIOPE-169479233781730/>



D9.3_ Record of Dissemination and Communication Activities



PRIMAGE
Medical imaging
Artificial intelligence
Childhood cancer research

Follow

Primage Project
@primage_project

Primage Project.
PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers.

primageproject.eu Joined September 2019

1 Following 29 Followers

Not followed by anyone you're following


Primage Project @primage_project · Oct 30
Thanks to all partners for another great PRIMAGE consortium meeting in Valencia!
#PRIMAGEProject

Ignacio Blanquer @iblanque · Oct 30
@primage_project face to face meeting at the @UPV



6 14

Primage Project @primage_project · Oct 4
Dr Martí-Bonmati presenting #PRIMAGEProject at the National Congress of Radiology and Medical Imaging in Sovata, Romania.



7 12

Primage Project Retweeted

MAngeles Pérez @mangelespa · Oct 30
Presenting multiscale models @primage_project #universytshellfield #ansys #unibo #chemotargets #cyfronet #unizar @M2BE_J3A @I3Aunizar @EINAunizar



8 19

Media

On the occasion of the celebration of the 1st PRIMAGE Consortium Meeting, HULAFE issued a press release on the EUROPEAN HOSPITAL newspaper.



16 ONCOLOGY

Spanish hospital coordinates €10 million EU project

Aiming at lethal paediatric tumours

La Fe University and Polytechnic Hospital in Valencia, Spain, is coordinating EU-funded program PRIMAGE, which uses precision information from medical imaging to advance knowledge of the most lethal paediatric tumours, by establishing their prognosis and expected treatment response using radiomics, imaging biomarkers and artificial intelligence (AI), Melisande Rouger reports.

About six months ago, the European Commission funded the PRIMAGE project with over €10M, to help improve treatment and identify a tumour's main characteristics without the need for biopsy, using computational processing of medical images on the cloud.

The PRIMAGE consortium will create a bank of images obtained through AI, using an open cloud-based platform to support decision-making in the clinical management of Neuroblastoma (NB), the most frequent solid cancer of early childhood, and Diffuse Intrinsic Pontine Glioma (DIPG), the leading cause of brain tumour-related death in children. The PRIMAGE platform will implement the latest advancement of in-silico imaging biomarkers and modeling of tumour growth towards a personalised diagnosis, prognosis and therapies follow-up.

The ambitious project involves 17 European partners, including several internationally recognised institutions, and four leading industrial partners, all of which are working under the scope of the Imaging Biomedical Research Group (GIB250) at the La Fe Research Institute in Valencia.

The great value brought by PRIMAGE is that the study will use real world data as a foundation to help identify the best treatment for each individual patient, instead of collecting sample data, as in prospective trials. Exploiting the information from existing imaging biobanks and patient clinical files using advanced computational methods will help significantly to improve decision making in cancer management, according to GIBI 2030 Director Luis Martí-Bonmati, Chairman of Radiology at La Fe Hospital.

Predicting disease right at the beginning

Using real world data in in-silico models can help establish imaging and molecular data's capacity to estimate and predict right from the beginning of disease, to ultimately make the best therapeutic decision for each patient. This has, to our knowledge, never been done before for any type of cancer in a multicentric approach and using such disruptive technology, Martí-Bonmati said.

Being able to precisely estimate tumour phenotypic aggressiveness, stage and extension, define the best treatment plan and establish the most accurate prognosis will definitely help paediatric oncologists improve their decision-making, he added.

PRIMAGE will use the latest available technology in the field of computing and AI, for example machine learning software developed by QIBIBI, a spin-off of La Fe's Research Institute that has received CE marks for its image post processing algorithms and is in charge for developing the PRIMAGE platform's architecture, adapt and design.

Knowledge acquired will benefit cancer

Cancer remains the first cause non-traumatic death among children, but it has a very low incidence in this population. Experts estimate that 500,000 EU citizens will be paediatric cancer survivors by 2025.

Neuroblastoma is the most common extracranial tumour in children and represents 10% of all paediatric cancers. In Europe, 35,000 cases are diagnosed each year, 10 in Spain alone.

Diffuse Intrinsic Pontine Glioma is a very rare disease in children and is associated with low survival rates and some research going but there is no curative treatment as yet.

PRIMAGE's scope on these diseases is expected to shed light on two of the less documented ones. Cancer is more rare in children than in adults. It is pertinent to the data from international imaging biobanks in this setting.

The PRIMAGE project team



In the same way, on the occasion of the celebration of the 2nd PRIMAGE Consortium Meeting, the Polytechnic University of Valencia who hosted the meeting, issued several press release about PRIMAGE project in different local media, including digital newspapers and a radio interview:

RADIO INTERVIEW - El Hospital La Fe y la Universidad Politécnica de Valencia buscan mejorar el diagnóstico del cáncer infantil con inteligencia artificial

Cadena Ser

Hora 14 Fin de Semana

<http://vlc19.almacen.api.auditmedia.es//api/Recortes/0d6ab442-d8bf-4670-9c0f-3a663b47d0c8/radio.mp3>



Edición C. Valenciana-

« EDICIÓN ESPAÑA | EFE Salud | EFE Verde | EFE Agro | Efeminista | Empresas | Emprende | Estilo | Futuro | Motor | Turismo | PracticoDeporte

Edición C. Valenciana Portada

CÁNCER INFANTIL

La Inteligencia Artificial ayudará a un mejor diagnóstico del cáncer infantil

EFE | Valencia | 25 oct. 2019



Investigación y tecnología se dan la mano en los avances en medicina. EFE/Archivo



El proyecto de investigación europeo PRIMAGE, liderado por el Instituto de Investigación Sanitaria La Fe y cuya reunión acoge la próxima semana la Universidad Politécnica de Valencia (UPV) aplica técnicas de Inteligencia Artificial (IA) para mejorar el diagnóstico y seguimiento del cáncer infantil.

PRIMAGE, que ayudará a caracterizar con más detalle los tumores pediátricos y a determinar el tratamiento más adecuado para cada paciente, trabaja en dos tipos de cáncer pediátrico que tienen una alta mortalidad y complejidad terapéutica: el neuroblastoma y el glioma difuso de troncoencéfalo (DIPG).

El investigador del Instituto de Instrumentación Molecular (UPV-CSIC-CIEMAT) Ignacio Blanquer ha explicado a EFE que las técnicas de IA y modelos computacionales en los que trabajan "permitirán obtener más información de las imágenes de Resonancia Magnética de cada paciente, sin tener que realizar una biopsia".

"Ayudarán a caracterizar con más detalle los tumores, así como a determinar el tratamiento más eficaz, conociendo con antelación la respuesta al mismo", ha añadido.

El proyecto, financiado por el programa Horizon2020 de la UE, comenzó a finales de 2018 y tiene una duración de cuatro años; en él, la UPV es responsable de la infraestructura de la nube y los servicios necesarios para el almacenamiento y proceso eficiente y seguro de los datos médicos.



DE AQUÍ EL PERIÓDICO



Comunitat València Alicante Castellón Morvedre L'H. Nord L'H. Sud C. Túria Utiel-Requena Palancia
EPDA Ciencia Sucesos En València

888 sport.es Exclusivo para nuevos jugadores
Hasta **150€** de bono de bienvenida!

APUESTA AHORA

Aplicar bonos y condiciones

INTELIGENCIA ARTIFICIAL

La Inteligencia Artificial ayudará a un mejor diagnóstico del cáncer infantil, según un proyecto de investigación del Instituto de Investigación Sanitaria La Fe de Valencia

'Ayudarán a caracterizar con más detalle los tumores, así como a determinar el tratamiento más eficaz, conociendo con antelación la respuesta al mismo', señala Ignacio Blanquer

EPX - 27/10/2019



Investigación y tecnología se dan la mano en los avances en medicina. EFE/Archivo

El proyecto de investigación europeo PRIMAGE, liderado por el Instituto de Investigación Sanitaria La Fe y cuya reunión acoge la próxima semana la Universidad Politécnica de Valencia (UPV) aplica técnicas de Inteligencia Artificial (IA) para mejorar el diagnóstico y seguimiento del cáncer infantil.

PRIMAGE, que ayudará a caracterizar con más detalle los tumores pediátricos y a determinar el tratamiento más adecuado para cada paciente, trabaja en dos tipos de cáncer pediátrico que tienen una alta mortalidad y complejidad terapéutica: el neuroblastoma y el glioma difuso de troncoencéfalo (DIPG).

El investigador del Instituto de Instrumentación Molecular (UPV-CSIC-CIEMAT) Ignacio Blanquer ha explicado a EFE que las técnicas de IA y modelos computacionales en los que trabajan 'permitirán obtener más información de las imágenes de Resonancia Magnética de cada paciente, sin tener que realizar una biopsia'.

'Ayudarán a caracterizar con más detalle los tumores, así como a determinar el tratamiento más eficaz, conociendo con antelación la respuesta al mismo', ha añadido.

El proyecto, financiado por el programa Horizon2020 de la UE, comenzó a finales de 2018 y tiene una duración de cuatro años; en él, la UPV es responsable de la infraestructura de la nube y los servicios necesarios para el almacenamiento y proceso eficiente y seguro de los datos médicos.



Quizá te interese...

Investigadores de la Politécnica de Valencia desarrollan una herramienta que localiza manuscritos en Archivos Históricos

El uso abusivo de móviles está aumentando los casos de miopía, según un experto ilicitano

El Hospital IMED Valencia realiza una nefrectomía parcial asistida por el robot Da Vinci

Nace BIOMATCH, el Tinder de los talentos científicos valencianos con empresas BIO de la Comunitat

La Ciudad de las Artes de Valencia homenajea a las mujeres dedicadas a la química

Se triplican en la última década los tratamientos con embriones donados

El IIS La Fe impulsará el proyecto 'Tu hospital investiga-La ciencia de cerca'

Una red de fibra óptica revela al momento la calidad del agua de los ríos



Proyecto Primage

Técnicas de Inteligencia Artificial ayudarán a mejorar el diagnóstico del cáncer infantil

El proyecto de investigación europeo, liderado por el Instituto de Investigación Sanitaria La Fe y cuya reunión acoge la próxima semana la UPV

Redacción E3



Archivado en: Cáncer infantil, Hospital La Fe, Proyecto Primage, Universitat Politècnica de València (UPV)



Fachada del Hospital La Fe de València E3

27/10/2019

El proyecto de investigación europeo Primage, liderado por el Instituto de Investigación Sanitaria La Fe y cuya reunión acoge la próxima semana la Universidad Politècnica de València (UPV) aplica técnicas de Inteligencia Artificial (IA) para mejorar el diagnóstico y seguimiento del cáncer infantil.

Primage, que ayudará a caracterizar con más detalle los tumores pediátricos y a determinar el tratamiento más adecuado para cada paciente, trabaja en dos tipos de cáncer pediátrico que tienen una alta mortalidad y complejidad terapéutica: el neuroblastoma y el glioma difuso de troncoencéfalo (DIPG).

El investigador del Instituto de Instrumentación Molecular (UPV-CSIC-CIEMAT) Ignacio Blanquer ha explicado a EFE que las técnicas de IA y modelos computacionales en los que trabajan "permitirán obtener más información de las imágenes de Resonancia Magnética de cada paciente, sin tener que realizar una biopsia".

"Ayudarán a caracterizar con más detalle los tumores, así como a determinar el tratamiento más eficaz, conociendo con antelación la respuesta al mismo", ha añadido.

El proyecto, financiado por el programa Horizon2020 de la UE, comenzó a finales de 2018 y tiene una duración de cuatro años; en él, la UPV es responsable de la infraestructura de la nube y los servicios necesarios para el almacenamiento y proceso eficiente y seguro de los datos médicos.

Los cánceres que afectan a los niños son diferentes a la de los adultos y los más frecuentes son las leucemias, los tumores cerebrales, linfomas y neuroblastomas

<http://metaclip.auditmedia.es/api/document/dossier/c61485f1-efbc-4023-a999-6c1b9bc08192?tknid=1caQwTE26k.FzSXOW33yzg--&tknmd=HON20FV80fYYcX5uoJjFAw-->

Further media dissemination of the press release was done by the University of Zaragoza, as well as a radio and TV interview:

https://www.eldiario.es/aragon/sociedad/Universidad-Zaragoza-lidra-investigacion-Mecanobiologia_0_865464477.html

https://www.elperiodicodearagon.com/noticias/aragon/investigadores-zaragoza-haran-simulaciones-virtuales-tumores_1334252.html

<https://www.unizar.es/noticias/investigadores-de-la-universidad-de-zaragoza-realizaran-simulacion-virtual-para-estudiar>

<https://www.lacomarca.net/simulacion-virtual-tumores-pediatricos/>



<https://elmedicointeractivo.com/europa-financia-investigadores-espanoles-en-el-estudio-de-los-tumores-pediatricos-mas-mortales/>

<http://historico.aragondigital.es/noticia.asp?notid=173212&secid=16&clas=1>

<https://www.europapress.es/aragon/noticia-investigadores-uz-realizaran-simulacion-virtual-estudiar-tumores-pediatricos-mas-mortales-20190104131732.html>

<https://www.economista.es/ecoaula/noticias/9817851/04/19/La-investigacion-de-la-Universidad-de-Zaragoza-despega-en-Europa.html>

<http://diarioaragones.com/mediodia/guerra-al-cncer-infantil/>

<https://www.heraldo.es/noticias/salud/2019/01/04/ingenieros-aplican-inteligencia-artificial-para-investigar-cancer-infantil-1285689-2261131.html>

https://www.eldiario.es/aragon/sociedad/Investigadores-Universidad-Zaragoza-realizaran-pediatricos_0_853914745.html

Radio:

<http://www.aragonradio.es/podcast/emision/agora-09012019-ingenieria-computacional-para-estudiar-tumores-pediatricos/>

TV:

M^a Angeles Pérez Ansón (UNIZAR) appeared at the Regional TV program (it is a science TV program) En ruta con la Ciencia:

<http://alacarta.aragontelevision.es/programas/en-ruta-con-la-ciencia/cap-122-tecnologia-medica-puntera-21022019-2303>

3. Evaluation

The dissemination activities have been evaluated continuously to measure the success of the strategies outlined in the initial Dissemination Plan.

The following quality indicators were measured and show the data from Jan 2019 until November 2019:

Dissemination Activities	Quality Indicators
Project website	Number of visitors: 690 Number of visits: 1371 Top referring sites: vis.uni-konstanz.de; cyfronet.krakow.pl; medexprim.com; quibim.com; ehealthnews.eu Top visiting countries: Spain, Italy, USA Top pages viewed
eNewsletters/eBlasts	One planned before end of year
Events	26 (see details in prior section)
Publications	Number of published: 1 currently under review Press: four press releases were published
Social Media	Number of subscribers: SIOPE 3681; PRIMAGE 29 Number of tweets: SIOPE 7370; PRIMAGE 6



	Number of retweets: Monthly average SIOPE 120; PRIMAGE 23 Use of the #PRIMAGEproject hashtag: approximately 50 times
--	--

4. Plan for Year 2

Building on the foundation and tools established in Year 1, the plan for communication and dissemination of the PRIMAGE project for Year 2 will focus on the following actions:

2020 Roadmap of events:

A representative from SIOP Europe or one of the partners will attend the events listed below in order to communicate about PRIMAGE. The events in red are potential new events of interest, which have not yet been confirmed. Partners will be asked to continue to update the spreadsheet to indicate any additional events they plan to attend or have attended.

Dissemination at External Events	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20
International Childhood Cancer Day			Blue									
ACCELERATE Congress			Blue									
European Congress of Radiology (ECR)			Blue	Blue								
American Association for Cancer Research Congress (AACR)				Blue								
HimSS20				Yellow								
Digital Health				Yellow								
European Society for Radiotherapy & Oncology (ESTRO38)					Blue							
dHealth 2020						Yellow						
5th EORTC Quality of Life Conference						Blue						
SIOP Europe Annual Meeting						Blue						
SIOP Europe Clinical Research Council (CRC)						Blue						
CCI Europe Annual Congress						Blue						
ASCO Annual Conference							Blue					
Childhood Cancer Awareness Month										Blue		
ECCO Summit										Blue		
SIOP International Congress											Blue	
Digital Health World Congress												Yellow
Dissemination at Internal Events												
PRIMAGE Consortium Meeting							Blue					Blue

Updated Brochure:

A first draft of the updated brochure has been prepared and is currently under review. The final version will be ready for production by the end of 2019.

eNewsletter



A first draft of the newsletter is under preparation, pending some additional content provided by selected partners. The first edition will be distributed by the end of 2019.

Website

The PRIMAGE website will be continuously updated as new developments occur throughout the project. The latest news will also be shared via the website.

Social Media

Continuous efforts will be made to communicate about PRIMAGE via the selected social media channels, encouraging additional followers/subscribers and retweets.

Publications/Media

During Year 2, at least one article will be published in the media.

“Prediction of Neuroblastoma patients’ prognosis by MR texture features.”

Cooperation with other EU-funded projects

As the PRIMAGE project progresses, cooperation with other EC-funded projects is foreseen. The initial list of potential projects to connect with are described in D9.2 – First Year Plan for Dissemination and Communication of Project Results.

Respective WP leaders should make contact with these projects if appropriate and SIOP Europe will facilitate an exchange of weblinks between these projects and the PRIMAGE project.

Summary of Quality Indicators that will be monitored:

Dissemination Activities	Quality Indicators
Project website	Number of visitors Number of visits Top referring sites Top visiting countries Top pages viewed
eNewsletters/eBlasts	Number sent Number of subscribers Open rate
Events	Number of events with PRIMAGE presence
Publications	Number of published: Abstracts Scientific Articles and Papers Press releases Interviews Articles Advertisements
Social Media	Number of subscribers Number of tweets Number of retweets Use of the #PRIMAGEproject hashtag



5. Project Documents

All project documents, templates and dissemination tools can be accessed from the Google Drive shared repository: <https://drive.google.com/drive/folders/1d8D6pbInuZd0bZZjDcP66vlfXAP17O9J>:

